"We Are the Champions": Victory for VICTORIA Trial.
作者信息
Hsich Eileen M
机构信息
Heart and Vascular Institute at the Cleveland Clinic, Cleveland, Ohio, USA; Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
出版信息
JACC Heart Fail. 2023 Sep;11(9):1258-1261. doi: 10.1016/j.jchf.2023.06.026. Epub 2023 Aug 9.
Abstract
摘要
相似文献
1
"We Are the Champions": Victory for VICTORIA Trial.《我们是冠军》：维多利亚试验取得胜利
JACC Heart Fail. 2023 Sep;11(9):1258-1261. doi: 10.1016/j.jchf.2023.06.026. Epub 2023 Aug 9.
2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial.一项多中心、随机、双盲、安慰剂对照的可溶性鸟苷酸环化酶刺激剂疗效和安全性的研究：VICTORIA 试验。
JACC Heart Fail. 2018 Feb;6(2):96-104. doi: 10.1016/j.jchf.2017.08.013. Epub 2017 Oct 11.
3
[Vericiguat-new treatment option for patients with heart failure : Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA)].[维立西呱——心力衰竭患者的新治疗选择：射血分数降低的心力衰竭患者维立西呱全球研究（VICTORIA）]
Internist (Berl). 2020 Sep;61(9):989-991. doi: 10.1007/s00108-020-00828-7.
4
Population Pharmacokinetics of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: An Integrated Analysis.维立西呱在射血分数降低的心力衰竭患者中的群体药代动力学：一项整合分析。
Clin Pharmacol Ther. 2022 Nov;112(5):1061-1069. doi: 10.1002/cpt.2712. Epub 2022 Aug 13.
5
Vericiguat: The First Soluble Guanylate Cyclase Stimulator for Reduction of Cardiovascular Death and Heart Failure Hospitalization in Patients With Heart Failure Reduced Ejection Fraction.维立西呱：首个可溶性鸟苷酸环化酶刺激剂，用于降低射血分数降低的心力衰竭患者的心血管死亡和心力衰竭住院风险。
J Pharm Pract. 2023 Aug;36(4):905-914. doi: 10.1177/08971900221087096. Epub 2022 Mar 31.
6
Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.维立西呱用于射血分数保留的恶化慢性心力衰竭患者：可溶性鸟苷酸环化酶刺激剂治疗射血分数保留的心力衰竭患者（SOCRATES-PRESERVED）研究结果
Eur Heart J. 2017 Apr 14;38(15):1119-1127. doi: 10.1093/eurheartj/ehw593.
7
Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study.SOCRATES-PRESERVED 研究：射血分数保留的心力衰竭患者中可溶性鸟苷酸环化酶刺激剂的患者报告结局。
Eur J Heart Fail. 2017 Jun;19(6):782-791. doi: 10.1002/ejhf.800.
8
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.维立西呱治疗射血分数降低的心力衰竭患者的疗效。
N Engl J Med. 2020 May 14;382(20):1883-1893. doi: 10.1056/NEJMoa1915928. Epub 2020 Mar 28.
9
Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum.射血分数降低的心力衰竭患者全风险谱中可溶性鸟苷酸环化酶刺激剂的研究
Eur J Heart Fail. 2022 Nov;24(11):2029-2036. doi: 10.1002/ejhf.2720. Epub 2022 Nov 16.
10
The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction.维立西呱在射血分数降低的心力衰竭治疗领域的地位。
Heart Fail Rev. 2022 Jul;27(4):1165-1171. doi: 10.1007/s10741-021-10146-1. Epub 2021 Jul 21.
本文引用的文献
1
Age, Sex, and Outcomes in Heart Failure With Reduced EF: Insights From the VICTORIA Trial.射血分数降低的心力衰竭患者的年龄、性别与预后：来自VICTORIA试验的见解
JACC Heart Fail. 2023 Sep;11(9):1246-1257. doi: 10.1016/j.jchf.2023.06.020. Epub 2023 Aug 9.
2
Sacubitril/valsartan vs ACEi/ARB at hospital discharge and 5-year survival in older patients with heart failure with reduced ejection fraction: A decision analysis approach.沙库巴曲缬沙坦与 ACEi/ARB 在射血分数降低的心力衰竭老年患者出院时和 5 年生存率的比较：决策分析方法。
Am Heart J. 2022 Aug;250:23-28. doi: 10.1016/j.ahj.2022.04.007. Epub 2022 May 4.
3
Heart Failure Subtypes and Cardiomyopathies in Women.女性心力衰竭亚型和心肌病。
Circ Res. 2022 Feb 18;130(4):436-454. doi: 10.1161/CIRCRESAHA.121.319900. Epub 2022 Feb 17.
4
Trends in heart failure-related cardiovascular mortality in rural versus urban United States counties, 2011-2018: A cross-sectional study.2011 - 2018年美国农村与城市县心力衰竭相关心血管死亡率趋势：一项横断面研究。
PLoS One. 2021 Mar 3;16(3):e0246813. doi: 10.1371/journal.pone.0246813. eCollection 2021.
5
Age-specific trends and outcomes of hospitalizations with acute heart failure in the United States.美国急性心力衰竭住院患者的年龄特异性趋势和结局。
Int J Cardiol. 2021 May 1;330:98-105. doi: 10.1016/j.ijcard.2021.02.031. Epub 2021 Feb 17.
6
Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017.1990 年至 2017 年，195 个国家和地区心力衰竭的负担及其根本原因。
Eur J Prev Cardiol. 2021 Dec 29;28(15):1682-1690. doi: 10.1093/eurjpc/zwaa147.
7
Sex-Specific Associations of Cardiovascular Risk Factors and Biomarkers With Incident Heart Failure.心血管危险因素和生物标志物与心力衰竭事件的性别特异性关联。
J Am Coll Cardiol. 2020 Sep 22;76(12):1455-1465. doi: 10.1016/j.jacc.2020.07.044.
8
MRAs in Elderly HF Patients: Individual Patient-Data Meta-Analysis of RALES, EMPHASIS-HF, and TOPCAT.老年 HF 患者中的 MRA：RALES、EMPHASIS-HF 和 TOPCAT 的个体患者数据荟萃分析。
JACC Heart Fail. 2019 Dec;7(12):1012-1021. doi: 10.1016/j.jchf.2019.08.017.
9
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF.达格列净在射血分数降低的心力衰竭中的疗效和安全性：来自 DAPA-HF 的见解。
Circulation. 2020 Jan 14;141(2):100-111. doi: 10.1161/CIRCULATIONAHA.119.044133. Epub 2019 Nov 17.
Zotero 插件